Yuanyang

EN中文

Practice

Hong Kong and US IPOs.
Nine completed listings, most of them life science and hard tech.

9*listings completed

Life scienceincluding Chapter 18A

Hard techincluding Chapter 18C

Sizes are given as ranges; years and roles are as filed. Further mandates in progress are not listed.

Life science

  1. Over HK$1.5bn

    2025 · Underwriter counselA clinical-stage biotech company listed under Chapter 18A, the largest such offering in four years. Counsel to the underwriters, from due diligence and underwriting agreement negotiations through to closing.

  2. Over HK$700m

    2025 · Company counselA late-stage biopharma whose first product is now commercialised, listed under Chapter 18A. Counsel to the issuer: drafting the prospectus, answering HKEX comments and negotiating the underwriting agreement.

  3. Over HK$300m

    2024 · Underwriter counselA leading life-science software and data platform, listed under Chapter 8.05. Counsel to the underwriters, from due diligence and underwriting agreement negotiations through to closing.

  4. Over HK$300m

    2023 · Company counselA clinical-stage biotech company listed under Chapter 18A. Counsel to the issuer: drafting the prospectus, answering HKEX comments and negotiating the underwriting agreement.

Hard tech

  1. Over US$300m

    2026 · Underwriter counselA leading computing-technology group, listed under Chapter 8.05. Counsel to the underwriters, from due diligence and underwriting agreement negotiations through to closing.

  2. Over US$150m

    2025 · Company counselA leading autonomous-driving technology company, listed under Chapter 8.05. Counsel to the issuer: drafting the prospectus, answering HKEX comments and negotiating the underwriting agreement.

  3. Over HK$1bn

    2025 · Underwriter counselA leading lithium-ion power and storage battery manufacturer, listed under Chapter 8.05. Counsel to the underwriters, from due diligence and underwriting agreement negotiations through to closing.

Consumer and media

  1. Over HK$700m

    2025 · Company counselA leading premium baby-products company, listed under Chapter 8.05. Counsel to the issuer: drafting the prospectus, answering HKEX comments and negotiating the underwriting agreement.

  2. Over HK$350m

    2022 · Company counselA leading variety-programme producer and IP operator, listed under Chapter 8.05. Counsel to the issuer: drafting the prospectus, answering HKEX comments and negotiating the underwriting agreement.